# Oxalate nitrate

An oxalate nitrate is a chemical compound or salt that contains oxalate and nitrate anions (NO$_3$$^−$ and C$_2$O$_4$$^{2-}$). These are mixed anion compounds. Some have third anions. Oxalate acts as a ligand, which normally complexes two metal atoms.

## Naming

An oxalate nitrate compound may also be called a nitrate oxalate. In chemical formulae, oxalate may be indicated by "ox". As a ligand oxalate is termed "oxalato", and nitrate, "nitrato".

## Production

Most oxalate nitrates are formed by crystallisation from water solutions. One issue is the insolubility of metal oxalates.

## Properties

On heating, oxalate nitrates lose NO$_2$, NO, CO, and CO$_2$ and form metal carbonates or oxides.

## Related

Related to these are the oxalate phosphates and oxalate perchlorates.

## List

| name | formula | ratio C$_2$O$_4$:NO$_3$ | mw | system | space group | unit cell Å | volume | density | properties |
| phen = 1,10-phenanthroline | [Cr(phen)$_2$(C$_2$O$_4$)]NO$_3$·H$_2$C$_2$O$_4$·H$_2$O | | | monoclinic | Cc | a=15.856 b=14.353 c=13.141 β=106.517° Z=4 | 2867 | 1.553 | orange |
| bpy = 2,2′-bipyridine | [Cr(bpy)$_2$(C$_2$O$_4$)]NO$_3$·1/2H$_2$C$_2$O$_4$·4H$_2$O | | | monoclinic | P2$_1$/c | a=10.5565 b=17.1770 c=14.8525 β=99.272° Z=4 | 2658.00 | 1.578 | orange |
| fac-triammin-aquo-oxalato-cobalt(III)-nitrate monohydrate, | fac-[Co(NH$_3$)$_3$(C$_2$O$_4$)(H$_2$O)]NO$_3$·H$_2$O | | | monoclinic | P2$_1$/n | a=7.853 b=10.000 c=13.192 β=105.06° | | | |
| | [Co(NH$_3$)$_4$(C$_2$O$_4$)]NO$_3$·H$_2$O | | | | P2$_1$2$_1$2$_1$ | a=7.944 b=9.90 c=12.700 Z=4 | 999.15 | 1.968 | |
| Oxalato di(1,10-phenanthroline-N,N′) cobalt(III) nitrate 3.88 hydrate | [Co(C$_{12}$H$_8$N$_2$)$_2$(C$_2$O$_4$)]NO$_3$·3.88H$_2$O | | 639.14 | orthorhombic | Ibca | a = 15.492 b = 17.938 c = 19.635 Z = 8 | 5457 | 1.556 | pink |
| ept = N-(2-aminoethyl)-1,3-diaminopropane | [(Ni(ept)H$_2$O)$_2$ox](NO$_3$)$_2$ | | | | | | | | |
| | Ni$_2$en$_4$(C$_2$O$_4$)(NO$_3$)$_2$ | | | | | | | | |
| bpy = 2,2′-bipyridine | [{Ni(bpy)$_2$}$_2$(μ-C$_2$O$_4$)](NO$_3$)$_2$·H$_2$C$_2$O$_4$ | | 1044.23 | triclinic | P1 | a 9.2921 b 12.8702 c 18.9812 α 84.660° β 75.969° γ 85.056° Z=2 | 2187.9 | 1.585 | violet |
| m-xpt = bis(pyridyltriazole) ligand | [Ni$_2$(m-xpt)$_2$(C$_2$O$_4$)](NO$_3$)$_2$ | | | | | | | | |
| dien = diethylenetriamine | (H$_3$dien)[Ni(NO$_3$)(C$_2$O$_4$)$_2$].2H$_2$O | | | monoclinic | P2$_1$/c | a=10.218 b=11.074 c=14.897 β=103.988° | | | blue |
| bpt = pyridyltriazole ligand | Cu$_2$(bpt)$_2$(NO$_3$)$_2$(DMF)$_2$(C$_2$O$_4$) | | | | | | | | |
| | [(Cu(ept))$_2$ox](NO$_3$)$_2$·H$_2$O | | | | | | | | |
| Diethylenetriammonium nitrato-bis(oxalato)cuprate (II) dihydrate | (H$_3$dien)[Cu(NO$_3$)(C$_2$O$_4$)$_2$].2H$_2$O | | | monoclinic | P2$_1$/c | a = 10.1054 b = 11.0825 c = 14.8238 β = 103.516° Z = 4 | 1614.2 | | |
| dien=diethylenetriamine | [Cu$_2$(C$_2$O$_4$)(dien)$_2$](NO$_3$)$_3$ | | | monoclinic | P2/c | a = 23.7888(10), b = 6.7055(3), c = 12.7842(6) and β = 95.534 | | | |
| Sparteine copper(II) nitrate oxalate | Cu$_2$(C$_{15}$H$_{26}$N$_2$)$_2$(NO$_3$)$_2$(C$_2$O$_4$) | 1:2 | | | | | | | light green |
| di-2-pyridylamine | Cu$_2$(dpyam)$_2$(μ-C$_2$O$_4$)(NO$_3$)$_2$(DMF)$_2$ | | | triclinic | P1 | a=8.353 b=9.100 c=12.245 α=72.035° β=75.228° γ=78.552° | | | |
| (μ$_2$-oxalato)-bis(di-2-pyridylamine)-bis(N,N',-dimethylformamide)-di-copper(ii) iodide nitrate | [Cu$_2$(dpyam)$_2$(μ-C$_2$O$_4$)(DMF)$_2$](I)$_{1.6}$(NO$_3$)$_{0.4}$ | | | triclinic | P1 | a=8.4616 b=8.9112 c=12.3824 α=71.913° β=76.329° γ=80.225° | | | |
| | Cu$_2$(dpyam)$_2$(C$_2$O$_4$)(NO$_3$)$_2$((CH$_3$)$_2$SO)$_2$] | | | | | | | | |
| | Cu$_2$(bpy)$_2$(C$_2$O$_4$)(NO$_3$)$_2$(H$_2$O)$_2$ | | | | | | | | |
| meprizole=(4-methoxy-2-(5-methoxy-3-methylo-pyrazol-1-yl)-6-methylpyrmadine) | [Cu$_2$(mepirizole)$_2$(C$_2$O$_4$)(NO$_3$)$_2$(H$_2$O)]$_2$[Cu$_2$(mepirizole)$_2$(C$_2$O$_4$)(NO$_3$)$_2$] | | | monoclinic | P2$_1$/c | a=20.073 b=13.842 c=11.451 β=119.09° Z=4 | | | |
| | Cu$_2$(histamine)$_2$(C$_2$O$_4$)(H$_2$O)$_2$(NO$_3$)$_2$ | | | triclinic | P1 | a=7.579 b=8.133 c=9.161 α=77.06° β=89.23° γ=82.54° Z=1 | 545.6 | | |
| | [Cu$_2$(bpy)$_2$(C$_2$O$_4$)(H$_2$O)$_2$][Cu(bpy)(C$_2$O$_4$)](NO$_3$)$_2$ | | | | | | | | |
| trimeen = N,N,N'-trimethylethylenediamine | [(Cu(trimeen)H$_2$O)$_2$ox](NO$_3$)$_2$ ·2H$_2$O | | | | | | | | |
| Pz$_2$CPh$_2$ = diphenyldipyrazolylmethane | Cu$_2$(Pz$_2$CPh$_2$)$_2$(NO$_3$)$_2$(μ-C$_2$O$_4$) | | | triclinic | P1 | a = 8.863 b = 10.241 c = 11.43 α = 98.98° β = 110.45° γ = 103.66° Z=2 | | | |
| Pz$^{3m}$$_2$CPh$_2$ = diphenylbis(3-methylpyrazolyl)methane | [Cu$_2$(Pz$^{3m}$$_2$CPh$_2$)$_2$(H$_2$O)$_2$(μ-C$_2$O$_4$)](NO$_3$)$_2$·H$_2$O | | | monoclinic | C2/c | a = 23.459 b = 8.8568 c = 21.782 β = 100.889° Z=4 | | | |
| phen = 1,10-phenanthroline; (μ$_2$-Oxalato-O,O',O'',O''')-diaqua-bis(1,10-phenanthroline)-di-copper(ii) dinitrate | [Cu$_2$(ox)(phen)$_2$(H$_2$O)$_2$](NO$_3$)$_2$ | | | monoclinic | P2$_1$/n | a=7.128 b=11.715 c=16.529 β=91.80° | | | |
| 4,4’-bipyridine; 1,10-phenanthroline; | [Cu$_2$(ox)(4,4’-bpy)(phen)$_2$](NO$_3$)$_2$ | | 855.72 | monoclinic | C2/c | a=23.144 b=10.6601 c=13.4363 β=93.123° Z=4 | 3310.4 | | green |
| Bipy = 2,2′-bipyridine; | Cu$_2$(Bipy)$_2$(H$_2$O)$_2$(C$_2$O$_4$)(NO$_3$)$_2$ | | | | | | | | |
| μ-oxalato-κ$^4$O$^1$,O$^2$:O$^{1′}$,O$^{2′}$-bis(aqua(nitrato-κO){[1-(2-pyridyl-κN)ethylidene]hydrazine-κN}copper(II)) μ-oxalato-κ$^4$O$^1$,O$^2$:O$^{1′}$,O$^{2′}$-bis((methanol-κO)(nitrato-κO){[1-(2-pyridyl-κN)ethylidene]hydrazine-κN}copper(II)) | [Cu$_2$(C$_2$O$_4$)(NO$_3$)$_2$(C$_7$H$_9$N$_3$)$_2$(H$_2$O)$_2$][Cu$_2$(C$_2$O$_4$)(NO$_3$)$_2$(C$_7$H$_9$N$_3$)$_2$(CH$_4$O)$_2$] | | | triclinic | P1 | a = 9.8358 b = 12.377 c = 12.714 α = 103.704° β = 112.573° γ = 107.821° Z = 1 | 1245.15 | | |
| (μ$_2$-oxalato)-bis(dimethylsulfoxido)-bis(di-2-pyridylamine)-dinitrato-di-copper(ii) | [Cu$_2$(dpyam)$_2$(C$_2$O$_4$)(NO$_3$)$_2$((CH$_3$)$_2$SO)$_2$ | | | triclinic | P1 | a 8.7190 b 8.9680 c 11.421 α 68.58° β 77.79° γ 80.58° | | | |
| (μ$_2$-Oxalato-O,O',O'',O''')-diaqua-bis(2,3-bis(2-pyridyl)pyrazine)-di-copper(ii) dinitrate tetrahydrate | [Cu$_2$(dpp)$_2$(H$_2$O)$_2$(NO$_3$)$_2$(ox)]·4H$_2$O | | | monoclinic | P2$_1$/c | a=9.704b=7.2598 c=25.865 β=97.395° | | | |
| L=4,4′-methylenebis(1-(2-pyridyl)-3,5-dimethylpyrazole; (μ$_2$-4,4'-Methylenebis(1-(2-pyridyl)-3,5-dimethylpyrazole))-bis(nitrato-O)-di-copper acetonitrile solvate | CuL(C$_2$O$_4$)(NO$_3$) | | | monoclinic | P2/n | a=8.5679 b=9.3862 c=20.5910 β=101.038° | | | |
| bis(μ$_2$-oxalato)-tetrakis(2,2'-bipyridine)-(oxalato)-di-copper(ii)-chromium(iii) nitrate monohydrate | [{Cu(μ-C$_2$O$_4$)(bpy)$_2$}$_2$Cr(C$_2$O$_4$)]NO$_3$·H$_2$O | | | monoclinic | C2/c | a=6.428 b=17.162 c=16.749 β=110.721° | | | |
| bis(tris(2,2'-bipyridine)-copper(ii)) tris(oxalato)-chromium(iii) nitrate nonahydrate | [Cu(bpy)$_3$]$_2$[Cr(C$_2$O$_4$)$_3$]NO$_3$·9H$_2$O | | | monoclinic | P2$_1$/c | a=31.314 b=13.536 c=22.202 β=132.01° | | | |
| (μ$_2$-Oxalato)-tetrakis(μ$_2$-N,N'-propane-1,3-bis(3-methoxysalicylideneiminato))-diaqua-bis(nitrato-O)-tetra-copper(ii)-di-neodymium(iii) dinitrate hexahydrate | [{(LCu$^{II}$(ONO$_2$))(LCu$^{II}$(H$_2$O))Nd$^{III}$}$_2$(μ-C$_2$O$_4$)](NO$_3$)$_2$ · 6H$_2$O | | | monoclinic | P2$_1$ | a=16.982 b=15.241 c=17.368 β=96.71° | | | |
| | (H$_3$O,N$_2$H$_5$)$_5${[Ce(H$_2$O)][Ce(NO$_3$)]$_2$(C$_2$O$_4$)$_6$}.6H$_2$O | | | tetragonal | P4$_3$2$_1$2 | a=11.6521 c=27.9597 | | | |
| | (H$_3$O,N$_2$H$_5$)$_2${Nd(C$_2$O$_4$)$_2$NO$_3$} | | | monoclinic | P2$_1$/c | a=9.296 b=17.214 c=9.214 β=116.586 | | | |
| | (H$_3$O,N$_2$H$_5$)$_2$(NO$_3$)$_2${Eu$_2$(H$_2$O)$_6$(C$_2$O$_4$)$_3$} | | | monoclinic | P2$_1$/n | a=8.0806 b=18.986 c=17.318 β=99.331° | | | |
| melaminium | [C$_3$H$_7$N$_6$]$_6$[Dy(C$_2$O$_4$)$_4$][NO$_3$] | | | triclinic | P1 | a=9.777 b=10.676 c=25.083 α=97.18° β=79.81° γ=86.52° | 2570 | | |
| melaminium | [C$_3$H$_7$N$_6$]$_6$[Ho(C$_2$O$_4$)$_4$][NO$_3$] | | | triclinic | P1 | a=9.760 b=10.660 c=25.051 α=87.24° β=87.24° γ=79.96° | 2559 | | |
| | (N$_2$H$_5$){Er(C$_2$O$_4$)$_2$}.$_2$H$_2$O | | | tetragonal | P4$_3$2$_1$2 | a=11.3348 c=9.2646 | | | |
| melaminium | [C$_3$H$_7$N$_6$]$_6$[Yb(C$_2$O$_4$)$_4$][NO$_3$] | | | triclinic | P1 | a=9.7297 b=10.5937 c=24.9904 α=87.271° β=80.123° γ=86.955° | 2532.15 | | |
| lead nitrate oxalate | Pb$_2$(NO$_3$)$_2$(C$_2$O$_4$)⋅2H$_2$O | | | monoclinic | P2$_1$/c | a=10.623 b=7.9559 c=6.1932 β=104.49° Z=4 | | | |
| | (OPb$_2$)$_2$(C$_2$O$_4$)(NO$_3$)$_2$ | | | monoclinic | P2$_1$/c | a=11.8682 b=5.2501 c=9.0989 β=96.741° | | | |
| μ-Oxalato-κ$^4$O$^1$,O$^2$:O$^{1′}$,O$^{2′}$-bis[aqua(2,2′-bipyridine-κN)(nitrato-κ$^2$O,O′)lead(II)] | Pb$_2$(C$_2$O$_4$)(NO$_3$)$_2$(C$_{10}$H$_8$N$_2$)$_2$(H$_2$O)$_2$ | | | monoclinic | P2$_1$/c | a=9.579 b=20.633 c=6.765 β=91.687° Z=2 | 1336.5 | | |
| bipy = 2,2′-bipyridine; (μ$_2$-oxalato)-bis(2,2'-bipyridine)-dinitrato-diaqua-di-lead | Pb$_2$(ox)(bipy)$_2$(NO$_3$)$_2$(H$_2$O)$_2$ | | | monoclinic | P2$_1$/c | a=9.5444 b=20.5956 c=6.7449 β=91.819° | | | |
| phen = 1,10-phenanthroline | {Pb(phen)$_2$}$_2$Cr(ox)$_2$(phen)][Cr(ox)$_2$(phen)](NO$_3$)$_2$ | | | triclinic | P1 | a 13.311 b 18.861 c 19.500 α 115.14° β 107.54° γ 96.28° | | | |
| | AgPb(C$_2$O$_4$)(NO$_3$) | | | | | | | | heat decompose to Ag and PbCO$_3$ |
| tetraethyldiglycolamide | [Th(TEDGA)$_2$(C$_2$O$_4$)][NO$_3$]$_2$[H$_2$C$_2$O$_4$].6H$_2$O | | 1128.86 | tetragonal | P4$_2$2$_1$2 | a=18.714 c=12.9212 Z=4 | 4525.2 | 1.657 | @100K Th is 10 coordinate |
| tetraethyldiglycolamide | [Th$_2$(C$_2$O$_4$)$_3$(TEDGA)$_4$][NO$_3$][HC$_2$O$_4$][H$_2$C$_2$O$_4$]$_4$.7H$_2$O | | 2340.47 | triclinic | P1 | a=15.6611 b=17.9082 c=18.1814 α=89.896° β=65.549° γ=87.623° Z=2 | 4637.2 | 1.676 | @100K is 10 coordinate, bicapped square antiprism |
| diammonium oxalatotetranitratouranylate | (NH$_4$)$_2$[{UO$_2$(NO$_3$)$_2$}$_2$(μ$_4$-C$_2$O$_4$)] · 2H$_2$O | 1:4 | | monoclinic | P2$_1$/c | a = 8.650 b = 11.700 c = 20.213 β = 93.92° Z = 4 | 2040.9 | | |
| Aqua-(2,2'-bipyridine)-bis(nitrato)-(μ$_2$-oxalato)-dioxo-uranium(vi)-copper(ii) | UO$_2$Cu(C$_2$O$_4$)(NO$_3$)$_2$(bipy)(H$_2$O) | | | triclinic | P1 | a 7.7582 b 11.0274 c 12.181 α 66.717° β 85.541° γ 87.653° | | | |
| (μ$_2$-2,2'-bipyrimidine)-bis(μ$_2$-oxalato)-bis(μ$_2$-hydroxo)-tetraoxo-bis(nitrato)-di-copper-di-uranium | [(UO$_2$)$_2$Cu$_2$(C$_2$O$_4$)$_2$(bipym)$_3$(OH)$_2$]·2NO$_3$ | | | triclinic | P1 | a 9.9169 b 10.9294 c 11.1783 α 103.449° β 110.754° γ 110.069° | | | |
| | [C$_6$H$_{14}$N]$_4$[UO$_2$(C$_2$O$_4$)$_2$(HC$_2$O$_4$)]NO$_3$·2H$_2$O | | 1033.86 | monoclinic | P2$_1$/c | a=11.9358 b=18.7279 c=19.1956 β=102.210° Z=4 | 4193.8 | 1.637 | |
| | [C$_8$H$_{18}$N][UO$_2$(C$_2$O$_4$)(NO$_3$)] | | | monoclinic | P2$_1$/c | a=11.3688 b=11.0238 c=13.4478 β=11.465° Z=4 | 1557.5 | 2.338 | |